Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0476 • ACR Convergence 2023
Factors Associated with the Need for Assisted Reproductive Therapies in a Spanish Cohort of Patients with Rheumatic Diseases
Antía García-Fernández¹, Fernando Rengifo-García¹, Raquel Senosiain-Echarte¹, Miguel álvaro-Navidad¹, Miguel A Gonzalez-Gay² and Juan A Martínez-López¹, ¹Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ²IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain
Background/Purpose: Patients with rheumatic diseases (RMD) have a lower pregnancy rate, with infertility being one of the main causes. The rate of assisted reproductive therapies…
Abstract Number: 0771 • ACR Convergence 2023
A Modified Idiopathic Pulmonary Fibrosis-Derived Composite Biomarker Score Is Associated with Interstitial Lung Disease Among U.S. Veterans with Rheumatoid Arthritis
Brent Luedders¹, Dana Ascherman², Daniel Kass³, Joshua Baker⁴, Michael Duryee¹, Yangyuna Yang¹, Punyasha Roul¹, K Wysham⁵, Paul Monach⁶, Andreas Reimold⁷, Gail Kerr⁸, Gary Kunkel⁹, Grant Cannon¹⁰, Jill Poole¹, Geoffrey Thiele¹, Ted R Mikuls¹¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵VA Puget Sound/University of Washington, Seattle, WA, ⁶VA Boston Healthcare System, Boston, MA, ⁷University of Texas Southwestern Medical Center, Dallas, TX, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹University of Utah, Salt Lake City, UT, ¹⁰University of Utah and Salt Lake City VA, Salt Lake City, UT, ¹¹Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Based on the overlap in peripheral blood biomarkers associated with rheumatoid arthritis interstitial lung disease (RA-ILD) and idiopathic pulmonary fibrosis (IPF), a composite biomarker…
Abstract Number: 0823 • ACR Convergence 2023
Sleep Disturbance Predicts Pain Interference in Patients with Early Rheumatoid Arthritis in a Prospective Real-World Cohort
Burcu Aydemir¹, Orit Schieir², Marie-France Valois³, Lutfiyya Muhammad¹, Jing Song¹, dorothy Dunlop¹, Susan Bartlett⁴, Louis Bessette⁵, Gilles Boire⁶, Glen Hazelwood⁷, Carol Hitchon⁸, Edward Keystone⁹, Janet Pope¹⁰, Carter Thorne¹¹, Diane Tin¹², Vivian Bykerk¹³, Yvonne Lee¹⁴ and Canadian Early Arthritis Cohort (CATCH) Investigators¹⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²McGill University, Montréal, QC, Canada, ³McGill University, Pointe-Claire, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, ⁶Université de Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Manitoba, Manitoba, MB, Canada, ⁹Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Newmarket Rheumatology Consultants, Newmarket, ON, Canada, ¹³Department of Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁴Northwestern University, Chicago, IL, ¹⁵CATCH, Winnipeg, MB, Canada
Background/Purpose: Despite taking strong immunosuppressive medications to control inflammation, many patients with rheumatoid arthritis (RA) continue to experience moderate to severe pain that does not…
Abstract Number: 0981 • ACR Convergence 2023
Time Trends in Overall Infection Risk in Patients with Inflammatory Arthritides Treated with Tumor Necrosis Factor Inhibitors
Aron Hjalti Bjornsson¹, Telma Thrastardottir², Bjorn Gudbjornsson³ and Thorvardur Love⁴, ¹Landspitali University Hospital and the University of Iceland, Reykjavík, Iceland, ²University of Iceland, Reykjavik, Iceland, ³Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁴Landspitali University Hospital and the University of Iceland, Reykjavik, Iceland
Background/Purpose: Infections are a known complication of disease-modifying therapy in rheumatic patients but have also been associated with the diseases being treated. Biosimilars have increased…
Abstract Number: 1033 • ACR Convergence 2023
The Detection of Subclinical Joint Inflammation by Thermal and Ultrasound Imaging at the Metacarpophalangeal Joints in Patients with Rheumatoid Arthritis
York Kiat Tan¹ and Gek Hsiang Lim², ¹Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ²Health Services Research Unit, Singapore General Hospital, Singapore, Singapore
Background/Purpose: While magnetic resonance imaging and ultrasound (US) imaging have been shown to be useful in the detection of subclinical joint inflammation in rheumatoid arthritis…
Abstract Number: 1264 • ACR Convergence 2023
Nomination of Biomarkers for Self-testing Disease Activity in Rheumatoid Arthritis Using Patient Similarity Networks: A Pilot Study
Martina Skacelova¹, Ondrej Janca², Milos Kudelka², Bishu Shrestha³, Pavel Horak⁴ and Eva Kriegova³, ¹Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic, ²Department of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Ostrava, Czech Republic, ³Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic, Olomouc, Czech Republic, ⁴Department of Internal Medicine III- Nephrology, Rheumatology, Endocrinology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
Background/Purpose: Although telemedicine in rheumatoid arthritis (RA) could improve disease control with lower healthcare costs, knowledge of suitable parameters for self-testing disease activity still remains…
Abstract Number: 1280 • ACR Convergence 2023
Systemic Inflammation Is Associated with Incident Valvular Heart Disease in Patients with Rheumatoid Arthritis: A Multicenter, Prospective Cohort Study
Tate Johnson¹, Yangyuna Yang¹, Punyasha Roul¹, Joshua Baker², Brian Sauer³, Grant Cannon⁴, Gary Kunkel⁵, Bryce Binstadt⁶, Amy Joseph⁷, K Wysham⁸, Aleksander Lenert⁹, Gail Kerr¹⁰, Andreas Reimold¹¹, Michael Duryee¹, Geoffrey Thiele¹, Ted R Mikuls¹² and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶University of Minnesota, Minneapolis, MN, ⁷Washington University / St. Louis VA, St. Louis, MO, ⁸VA Puget Sound/University of Washington, Seattle, WA, ⁹University of Iowa, Iowa City, IA, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹University of Texas Southwestern Medical Center, Dallas, TX, ¹²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The risk of aortic stenosis is increased in people with RA and valvular heart disease (VHD) is among the most over-represented causes of cardiovascular…
Abstract Number: 1296 • ACR Convergence 2023
Decline in Incidence of Extraarticular Manifestations of Rheumatoid Arthritis: A Population-Based Cohort Study
Bradly Kimbrough¹, Cynthia Crowson¹, John Davis¹, Eric Matteson² and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN
Background/Purpose: Extraarticular manifestations of rheumatoid arthritis (ExRA) are associated with increased disease burden and mortality. They are also common, affecting about half of patients with…
Abstract Number: 1312 • ACR Convergence 2023
Uncovering Risk Factors for Adverse Events and Infections in Rheumatoid Arthritis and Rheumatoid Arthritis with Interstitial Lung Disease Under Biologics or Targeted Synthetic DMARDs: Insights from the KOBIO Registry
Ji-Won Kim¹, Ju-Yang Jung¹, Chang-Hee Suh² and Hyoun-Ah Kim¹, ¹Ajou University School of Medicine, Suwon, South Korea, ²Ajou University Hospital, Suwon, South Korea
Background/Purpose: This study aimed to identify risk factors associated with adverse events (AEs) and infections in patients with rheumatoid arthritis (RA) and comorbid interstitial lung…
Abstract Number: 1329 • ACR Convergence 2023
R851, a Potent Second Generation IRAK1 and IRAK4 Inhibitor Suppresses IL-6 in Vitro and in Vivo for the Treatment of Rheumatoid Arthritis
Yan Chen¹, Sothy Yi¹, Vadim Markovtsov¹, Bhushan Samant¹, Andrew Chow¹, Esteban Masuda¹ and Simon Shaw², ¹Rigel Pharmaceuticals, Inc, South San Francisco, CA, ²Rigel Pharmaceuticals, Inc., South San Francisco, CA
Background/Purpose: The Toll-Like Receptor family (except TLR3) signal through IRAK4 and IRAK1 to produce an array of cytokines (including IL-6, IL-23 and TNFα in response…
Abstract Number: 1345 • ACR Convergence 2023
Maternal and Infant Outcomes Following Abatacept Exposure During Pregnancy
Michelle Ann Caesar, Diana Johnson, Kenneth Lyons Jones and Christina Chambers, University of California San Diego, La Jolla, CA
Background/Purpose: Abatacept is approved for the treatment of moderate to severe rheumatoid arthritis (RA) and psoriatic arthritis. However, there are limited data on the safety…
Abstract Number: 1675 • ACR Convergence 2023
Survival in Patients with Rheumatoid Arthritis and Early Breast Cancer Treated with Tumor Necrosis Factor Inhibitors
Maria Suarez-Almazor¹, Juan Ruiz², Xiudong Lei², Chi-Fang Wu², Hui Zhao², Suja Rajan³, Heather Lin² and Sharon Giordano², ¹MD Anderson Cancer Center, Houston, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³University of Texas School of Public Health, Houston, TX
Background/Purpose: There have been concerns about the use of tumor necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) and concomitant cancer. Few studies…
Abstract Number: 1730 • ACR Convergence 2023
Gut Microbiota Dysbiosis Impact Autonomic Function in Rheumatoid Arthritis Patients
Rachel AUDO¹, Jérome Thireau², Louis Rauzier³, Marie Barozet¹, JACQUES MOREL⁴, Patrice Bideaux³, alain Lacampagne² and Claire Daien⁵, ¹CHU Montpellier, Montpellier, France, ²PhyMedExp INSERM U1046, Montpellier, France, ³PhyMedExp U1046, Montpellier, France, ⁴Protocole thérapeutique immuno-rhumatologie, Montpellier, France, ⁵University Hospital, Montpellier, France
Background/Purpose: Rheumatoid arthritis (RA) is associated with a high risk of cardiovascular (CV) risks, including accelerated atherosclerosis, left ventricular hypertrophy and decreased heart rate variability…
Abstract Number: 1746 • ACR Convergence 2023
Smoking as a Risk Factor for Rheumatoid Arthritis: Exclusive Association with IgA Autoantibodies
Tineke van Wesemael¹, Anna Svärd², Annemarie Dorjee¹, Thomas Huizinga¹, René Toes¹ and Diane van der Woude¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Centre for Clinical Research Dalarna, Uppsala, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is characterized by autoantibodies to anti-modified protein autoantibodies (AMPAs) like anti-citrullinated protein antibodies (ACPA) and anti-acetylated protein antibodies (AAPA). Smoking is…
Abstract Number: 1762 • ACR Convergence 2023
Single-cell RNA Sequencing Analysis and Immune Profiling of Antigen-specific T Cells in Patients with Rheumatoid Arthritis and Healthy Controls
JING SONG¹, Cliff Rims¹, Matthew Dufort¹, Peter Linsley¹, Eddie James² and Jane Buckner², ¹Benaroya Research Institute, Seattle, WA, ²Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: Single-cell analysis has emerged as a powerful tool for investigating the transcriptomics and T-cell receptor (TCR) diversity in patients with rheumatoid arthritis (RA). However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].